UnicoCell Biomed Co., Ltd. (TPE:6794)
Taiwan · Delayed Price · Currency is TWD 62.50
+0.50 (0.81%)
Jul 22, 2025, 1:03 PM CST
UnicoCell Biomed Income Statement
Financials in millions TWD. Fiscal year is January - December.
Millions TWD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2017 - 2019 |
|---|---|---|---|---|---|---|---|
Period Ending | Mar '25 Mar 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2017 - 2019 |
| 39.06 | 31.88 | 24.59 | 14.4 | 8.18 | 3.98 | Upgrade | |
Revenue Growth (YoY) | 66.95% | 29.66% | 70.79% | 76.07% | 105.35% | -74.70% | Upgrade |
Cost of Revenue | 12.97 | 11.31 | 6.69 | 6.2 | 2.35 | 1.64 | Upgrade |
Gross Profit | 26.09 | 20.57 | 17.9 | 8.2 | 5.83 | 2.34 | Upgrade |
Selling, General & Admin | 35.75 | 34.85 | 31.4 | 25.4 | 23.3 | 21.94 | Upgrade |
Research & Development | 91.01 | 88.64 | 82.78 | 74.91 | 69.87 | 91.76 | Upgrade |
Operating Expenses | 126.76 | 123.49 | 114.18 | 100.31 | 93.17 | 113.69 | Upgrade |
Operating Income | -100.67 | -102.92 | -96.28 | -92.11 | -87.34 | -111.35 | Upgrade |
Interest Expense | -1.44 | -1.47 | -1.45 | -1.26 | -0.66 | -0.94 | Upgrade |
Interest & Investment Income | 8.03 | 7.54 | 5.79 | 0.84 | 0.08 | 0.36 | Upgrade |
Currency Exchange Gain (Loss) | 0 | 0.02 | 0.01 | 0.05 | - | - | Upgrade |
Other Non Operating Income (Expenses) | 5.1 | 5.13 | 3.04 | 1.18 | 1.54 | 2.73 | Upgrade |
EBT Excluding Unusual Items | -88.98 | -91.7 | -88.9 | -91.3 | -86.37 | -109.21 | Upgrade |
Gain (Loss) on Sale of Investments | -0.93 | -1.79 | - | 0.1 | - | - | Upgrade |
Gain (Loss) on Sale of Assets | - | 0.41 | 4.79 | - | - | - | Upgrade |
Other Unusual Items | - | - | - | 0.05 | - | - | Upgrade |
Pretax Income | -89.9 | -93.07 | -84.11 | -91.16 | -86.37 | -109.21 | Upgrade |
Net Income | -89.9 | -93.07 | -84.11 | -91.16 | -86.37 | -109.21 | Upgrade |
Net Income to Common | -89.9 | -93.07 | -84.11 | -91.16 | -86.37 | -109.21 | Upgrade |
Shares Outstanding (Basic) | 58 | 57 | 54 | 41 | 38 | 36 | Upgrade |
Shares Outstanding (Diluted) | 58 | 57 | 54 | 41 | 38 | 36 | Upgrade |
Shares Change (YoY) | 4.79% | 6.68% | 29.61% | 10.12% | 6.10% | 17.04% | Upgrade |
EPS (Basic) | -1.54 | -1.62 | -1.56 | -2.20 | -2.29 | -3.07 | Upgrade |
EPS (Diluted) | -1.54 | -1.62 | -1.56 | -2.20 | -2.29 | -3.07 | Upgrade |
Free Cash Flow | -76.26 | -66.84 | -81.35 | -78.05 | -85.34 | -148.85 | Upgrade |
Free Cash Flow Per Share | -1.31 | -1.17 | -1.51 | -1.88 | -2.27 | -4.19 | Upgrade |
Gross Margin | 66.81% | 64.52% | 72.78% | 56.93% | 71.32% | 58.71% | Upgrade |
Operating Margin | -257.73% | -322.83% | -391.56% | -639.78% | -1068.08% | -2796.43% | Upgrade |
Profit Margin | -230.16% | -291.94% | -342.06% | -633.15% | -1056.30% | -2742.57% | Upgrade |
Free Cash Flow Margin | -195.22% | -209.66% | -330.82% | -542.15% | -1043.70% | -3737.95% | Upgrade |
EBITDA | -82.74 | -82.37 | -76.71 | -76.25 | -71.24 | -98.68 | Upgrade |
EBITDA Margin | -211.83% | -258.35% | - | - | - | - | Upgrade |
D&A For EBITDA | 17.93 | 20.56 | 19.57 | 15.86 | 16.1 | 12.67 | Upgrade |
EBIT | -100.67 | -102.92 | -96.28 | -92.11 | -87.34 | -111.35 | Upgrade |
Updated Mar 3, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.